(Q37242251)

19 August 2017

1 reference

title

Maribavir: a novel antiviral agent with activity against cytomegalovirus (English)

1 reference

19 August 2017

0 references

Jennifer Trofe

1

1 reference

19 August 2017

Lindsey Pote

2

1 reference

19 August 2017

Erin Wade

3

1 reference

19 August 2017

Emily Blumberg

4

1 reference

19 August 2017

Roy D Bloom

5

1 reference

19 August 2017

language of work or name

English

0 references

publication date

12 August 2008

1 reference

Annals of Pharmacotherapy

19 August 2017

published in

1 reference

19 August 2017

volume

42

1 reference

19 August 2017

issue

10

1 reference

19 August 2017

page(s)

1447-1457

1 reference

The history of cytomegalovirus and its diseases

19 August 2017

cites work

1 reference

Antiviral drugs for cytomegalovirus diseases

21 January 2018

1 reference

Clinical and immunologic aspects of cytomegalovirus infection in solid organ transplant recipients

21 January 2018

1 reference

Infection in solid-organ transplant recipients

21 January 2018

1 reference

Canadian society of transplantation consensus workshop on cytomegalovirus management in solid organ transplantation final report

21 January 2018

1 reference

Cytomegalovirus in transplantation - challenging the status quo.

21 January 2018

1 reference

Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants.

21 January 2018

1 reference

Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients

21 January 2018

1 reference

Antiviral dosing and efficacy for prophylaxis of cytomegalovirus disease in solid organ transplant recipients

21 January 2018

1 reference

Pharmacokinetics of valganciclovir and ganciclovir in renal impairment

21 January 2018

1 reference

Oral ganciclovir dosing in transplant recipients and dialysis patients based on renal function.

21 January 2018

1 reference

Pharmacokinetics and safety of high-dose oral acyclovir for suppression of cytomegalovirus disease after renal transplantation

21 January 2018

1 reference

Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group.

21 January 2018

1 reference

A randomized, controlled trial comparing ganciclovir to ganciclovir plus foscarnet (each at half dose) for preemptive therapy of cytomegalovirus infection in transplant recipients

21 January 2018

1 reference

A prospective evaluation of leflunomide therapy for cytomegalovirus disease in renal transplant recipients

21 January 2018

1 reference

Antiviral medications to prevent cytomegalovirus disease and early death in recipients of solid-organ transplants: a systematic review of randomised controlled trials.

21 January 2018

1 reference

Potent and selective inhibition of human cytomegalovirus replication by 1263W94, a benzimidazole L-riboside with a unique mode of action

21 January 2018

1 reference

The human cytomegalovirus UL97 protein kinase, an antiviral drug target, is required at the stage of nuclear egress

21 January 2018

1 reference

21 January 2018

1 reference

Maribavir sensitivity of cytomegalovirus isolates resistant to ganciclovir, cidofovir or foscarnet

21 January 2018

1 reference

Accelerated evolution of maribavir resistance in a cytomegalovirus exonuclease domain II mutant

21 January 2018

1 reference

Cytomegalovirus UL97 mutations in the era of ganciclovir and maribavir

21 January 2018

1 reference

In vitro activities of benzimidazole D- and L-ribonucleosides against herpesviruses

21 January 2018

1 reference

Phase I safety and pharmacokinetic trials of 1263W94, a novel oral anti-human cytomegalovirus agent, in healthy and human immunodeficiency virus-infected subjects

21 January 2018

1 reference

Phase I dose escalation trial evaluating the pharmacokinetics, anti-human cytomegalovirus (HCMV) activity, and safety of 1263W94 in human immunodeficiency virus-infected men with asymptomatic HCMV shedding

21 January 2018

1 reference

Effect of ketoconazole on the pharmacokinetics of maribavir in healthy adults

21 January 2018

1 reference

Maribavir pharmacokinetics and the effects of multiple-dose maribavir on cytochrome P450 (CYP) 1A2, CYP 2C9, CYP 2C19, CYP 2D6, CYP 3A, N-acetyltransferase-2, and xanthine oxidase activities in healthy adults

21 January 2018

1 reference

Maribavir prophylaxis for prevention of cytomegalovirus infection in allogeneic stem cell transplant recipients: a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study

21 January 2018

1 reference

Interactions of 1263W94 with other antiviral agents in inhibition of human cytomegalovirus replication.

21 January 2018

1 reference

Maribavir antagonizes the antiviral action of ganciclovir on human cytomegalovirus

21 January 2018

1 reference

Focus on new drugs in development against human cytomegalovirus

21 January 2018

1 reference

Oral Valganciclovir Is Noninferior to Intravenous Ganciclovir for the Treatment of Cytomegalovirus Disease in Solid Organ Transplant Recipients

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1345/APH.1L065

1 reference

19 August 2017

1 reference